- Home
- NDLS vs MIST Comparison
NDLS vs MIST Comparison
Compare NDLS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- MIST
- Stock Information
- Founded
- NDLS 1995
- MIST 2003
- Country
- NDLS United States
- MIST Canada
- Employees
- NDLS N/A
- MIST N/A
- Industry
- NDLS Restaurants
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- MIST Health Care
- Exchange
- NDLS Nasdaq
- MIST Nasdaq
- Market Cap
- NDLS 45.2M
- MIST 53.9M
- IPO Year
- NDLS 2013
- MIST N/A
- Fundamental
- Price
- NDLS $0.74
- MIST $1.54
- Analyst Decision
- NDLS Strong Buy
- MIST Strong Buy
- Analyst Count
- NDLS 2
- MIST 2
- Target Price
- NDLS $3.00
- MIST $9.50
- AVG Volume (30 Days)
- NDLS 133.2K
- MIST 1.2M
- Earning Date
- NDLS 05-07-2025
- MIST 05-14-2025
- Dividend Yield
- NDLS N/A
- MIST N/A
- EPS Growth
- NDLS N/A
- MIST N/A
- EPS
- NDLS N/A
- MIST N/A
- Revenue
- NDLS $495,670,000.00
- MIST N/A
- Revenue This Year
- NDLS $5.37
- MIST N/A
- Revenue Next Year
- NDLS $0.68
- MIST N/A
- P/E Ratio
- NDLS N/A
- MIST N/A
- Revenue Growth
- NDLS N/A
- MIST N/A
- 52 Week Low
- NDLS $0.55
- MIST $0.63
- 52 Week High
- NDLS $2.20
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- NDLS 31.20
- MIST 65.88
- Support Level
- NDLS $0.79
- MIST $1.35
- Resistance Level
- NDLS $0.95
- MIST $1.44
- Average True Range (ATR)
- NDLS 0.09
- MIST 0.10
- MACD
- NDLS -0.01
- MIST 0.04
- Stochastic Oscillator
- NDLS 6.22
- MIST 100.00
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).